Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. G. Corrie, A. Marshall, P. D. Nathan, P. Lorigan, M. Gore, S. Tahir, G. Faust, C. G. Kelly, M. Marples, S. J. Danson, E. Marshall, S. J. Houston, R. E. Board, A. M. Waterston, J. P. Nobes, M. Harries, S. Kumar, A. Goodman, A. Dalgleish, A. Martin-ClavijoS. Westwell, R. Casasola, D. Chao, A. Maraveyas, P. M. Patel, C. H. Ottensmeier, D. Farrugia, A. Humphreys, B. Eccles, G. Young, E. O. Barker, C. Harman, M. Weiss, K. A. Myers, A. Chhabra, S. H. Rodwell, J. A. Dunn, M. R. Middleton

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science